vs
Side-by-side financial comparison of NOVO NORDISK A S (NVO) and TAKEDA PHARMACEUTICAL CO LTD (TAK), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q2 25 | — | $4.3M | ||
| Q1 24 | — | $4.0M |
| Q2 25 | — | $144.2K | ||
| Q1 24 | — | $317.0K |
| Q2 25 | — | 66.5% | ||
| Q1 24 | — | 69.1% |
| Q2 25 | — | 5.0% | ||
| Q1 24 | — | 12.2% |
| Q2 25 | — | 3.4% | ||
| Q1 24 | — | 7.9% |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
